Medroxyprogesterone acetate injectable suspension recall: CGMP Deviations
Medroxyprogesterone acetate injectable suspension, USP, 150 mg/mL, 1 mL vials, packaged in a) single dose vial (NDC 0703-6801-01), b) 25-count box single dose vials (NDC 0703-6801-04), Rx only, MFG: Teva Pharma USA
Why was Medroxyprogesterone acetate injectable suspension recalled?
cGMP deviations: Temperature abuse
What should I do if I have this product?
Review the official FDA enforcement record for current instructions.
What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.
Is my product affected?
Compare the item in your hand with every identifier below from the official FDA record. Only products that match the listed product and lot, UPC or model codes are part of this recall.
Which lot codes, UPCs or models are affected?
McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that impacted product may have been shipped to the customer.
- Product
- Medroxyprogesterone acetate injectable suspension, USP, 150 mg/mL, 1 mL vials, packaged in a) single dose vial (NDC 0703-6801-01), b) 25-count box single dose vials (NDC 0703-6801-04), Rx only, MFG: Teva Pharma USA
- Recalling firm
- Mckesson Medical-Surgical Inc. Corporate Office
- Quantity
- 89 cartons/25 vials per carton and 3 cartons/1 vial
- Distribution
- USA nationwide.
- Recall date
- June 15, 2022
- Classification
- Class II
- Status
- Terminated
- Agency
- FDA (drug)